Drug manufacturers are rushing to test a new type of coronavirus vaccine

As countries closed borders for travelers from southern Africa to avoid the spread of the virus that causes Covid-19, vaccinators were rushing to get their hands tested to see if their drugs were still working.

The World Health Organization raised the alarm Thursday regarding a variance of B.1.1.529 – now known as “Omicron” – which has a number of adaptive issues. But Moderna said their team has been working “non-stop” over the past few days, with BioNTech researchers using a pseudovirus – designed to look like a new strain – with the aim of finding out if their vaccine could be effective against the virus. stress within the next two weeks.

Johnson & Johnson said they were already testing its vaccine against the virus, with scientists at Oxford University hoping to introduce the virus soon, according to someone familiar with the matter. AstraZeneca says it is already conducting research in Botswana and Eswatini, where these species are located, to monitor the development of the new vaccine.

Vaccinators are enjoying the well-known rodeo. He also tested the lab tests as the Alpha, Beta and Delta models were discovered. It waiting for new updates and have been preparing for clinical trials to test new species. AstraZeneca has been set up to deliver results for its first modified vaccine, thanks to a version of Beta, recently, and Pfizer and BioNTech are testing the Alpha vaccine and. Different species of Delta.

But this is the first time that some species have shown significant changes in an important area: the “spike” protein used to transmit human cells. Francois Balloux, a professor at UCL Genetics Institute, said the change meant that antibodies that protect people who have been vaccinated or infected may not be aware of this.

Jo Walton, an expert at Credit Suisse, said all of the vaccines approved here are focused on spike protein, so they may all be less protective.

But mRNA vaccines need to be flexible because they only supply genes in small amounts of fat, and then use the body as a factory to make proteins that the body’s immune system needs to recognize. These symptoms can be modified rapidly and there is no need to spend as much time growing cells in tanks that require other types of vaccine.

“mRNA has to be simple: you can take a new cassette and put it in and if you want it, you have to make a new vaccine,” Walton said.

Shares in mRNA vaccine manufacturers jumped on Friday: Moderna rose 21 percent, BioNTech gained 17 percent and Pfizer 7 percent. CureVac was up 12.5 percent even though it had a valid vaccine. The German company said it could test the vaccine with a GSK partner within a few weeks.

BioNTech reported that Pfizer had taken action “months ago” to change the mRNA vaccine they had produced together within six weeks and send the original units within 100 days, should there be any “differences”.

Pfizer recently said it had cut the time from the start of the process to putting vaccines in bottles from 110 days to 31 days.

Although adenovirus vector vaccines such as Oxford / AstraZeneca and Johnson & Johnson jabs are also easy to modify, they are very difficult to develop. Michael Leuchten, a UBS expert, said this is reflected in the challenges AstraZeneca faced in production earlier this year.

“Adenovirus vectors do not like to grow. They hate it,” he said.

One vaccine that could benefit from it here is being reviewed by regulators. The weakened Valneva vaccine teaches the immune system how to detect other important proteins and spike. Consumption rates for French vaccines went up 8.5 percent on Friday as they hoped they could address some of the challenges.

The EU recently approved the purchase up to 60m Valneva level but the UK, which helped expand the Scottish Valneva factory, came from his union with the company in September.

If a country needs a vaccine in line with this new type, or other future challenges, governments, regulators and WHO should decide when to change.

Clive Dix, a former head of the immunization program in the UK government, said it was important to monitor the prevalence of the disease in people who have been vaccinated.

“Unfortunately, the data will not be created in the lab, it will be real global in the human population,” he said. “If, after examining people who have been vaccinated in South Africa, around them, they find that they are very sick, then a warning bell should start vaccinating – and soon.”

Richard Hatchett, executive director of the Coalition for Epidemic Preparedness Innovations, said the recent changes emphasize the need for research and development of the Covid vaccine. “It is very important that we continue to vaccinate people around the world. . . but we must also look at the efforts and resources to develop the current Covid-19 vaccine to help them better in the fight against multiple strains, “he said.

Treatment of antibodies

If the vaccine does not work well, Covid treatment will be very important.

Rafael Bayarri Olmos, an immunologist and researcher at Copenhagen University Hospital’s Laboratory of Molecular Medicine, said these differences could threaten antibodies.

The immune system against the vaccine can work against the entire spike protein, but antibody treatment focuses primarily on the receptor binding phase where the virus binds to the cells, he said. Version B.1.1.529 has 15 modifications in this area.

“These differences could make the vaccine less effective and less effective,” Olmos said. But it can make some antibody drugs “ineffective”.

An earlier Bloom Lab review at the Fred Hutchinson Cancer Research Institute in Seattle predicted that antibody treatment from AstraZeneca and GlaxoSmithKline would be more likely to address this new problem than the previous generation from Regeneron and Eli Lilly.

AstraZeneca said it is testing its treatment but believes it will still work because it combines two antibodies that work differently.

Sajid Javid, the UK health secretary, said Friday that the new change could affect the power of “one of the great drugs”: Ronapreve, developed by Regeneron.

Biotech from New York said it is testing its existing and future antibodies in future generations, including those already in clinical trials.

Antiviruses

That was “the good news.” antivirus those used in Covid therapy work differently than vaccines, so they will not be affected by changes in spike proteins, Walton said.

Kin-Chow Chang, a professor at the University of Nottingham who studies respiratory viral antiviruses, said the changes highlight the need for this type of treatment. He was working one job as the “second line of defense”.

Pfizer and Merck recently also reported long-term trial results on their antiretroviral drugs and the latter were approved in the UK. Merck Friday modified floor Its useful data for monitoring all outcomes, showing that its treatment reduced hospital risk and death by 30 percent, not 50 percent.

But pharmaceutical companies have not been able to develop antiviruses to the extent that they would need if the new breed was introduced. Merck expects to have 10m training by the end of the year, with Pfizer set to train only 180,000. Companies share their expertise with generic manufacturers but also take some time to prepare.

“It’s a good insurance policy, but I don’t think it will be anywhere,” said Leuchten of UBS.

Chang said the manufacturers may have been “patient” about the potential for their antivirals against new strains – but they are still willing to try.

“The first to have data that shows that it works against the latest developments will gain greater market awareness,” he said.

Additional reports by Oliver Barnes in London